Related Experiment Video

Updated: Mar 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Sflt-1 in heart failure: relation with disease severity and biomarkers

Damien Gruson1,2, Michel P Hermans1, Benjamin Ferracin1

  • 1a Pôle de Recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique , Cliniques Universitaires St-Luc and Université Catholique de Louvain , Brussels , Belgium ;

Scandinavian Journal of Clinical and Laboratory Investigation
|June 14, 2016
PubMed

Insights

Soluble fms-like tyrosine kinase-1 (sFlt-1) is elevated in heart failure (HF) patients, correlating with disease severity and cardiovascular risk biomarkers. This suggests sFlt-1 may serve as a novel biomarker for HF and associated risks.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of vascular endothelial growth factors.
  • sFlt-1 plays a role in modulating cardiovascular remodeling.
  • Understanding sFlt-1 levels in cardiovascular diseases is crucial for risk assessment.

Purpose of the Study:

  • To determine sFlt-1 levels in patients with heart failure (HF).
  • To investigate the relationship between sFlt-1 and adverse cardiovascular (CV) events.
  • To explore the association of sFlt-1 with biomarkers of CV risk and compare levels in HF, type 2 diabetes mellitus (T2DM), and healthy individuals.

Main Methods:

  • Measurement of sFlt-1 and placental growth factor (PlGF) levels in patient cohorts.
  • Correlation analysis of sFlt-1 concentrations with established HF severity markers and CV risk biomarkers.
  • Comparative analysis of sFlt-1 levels across HF, T2DM, and healthy control groups.

Main Results:

  • sFlt-1 and PlGF levels were significantly increased in HF patients compared to T2DM patients and healthy subjects (p < 0.01).
  • sFlt-1 concentration was strongly associated with HF severity (p < 0.001).
  • sFlt-1 levels correlated with NT-proBNP, soluble ST2, Galectin-3, aldosterone, and PTH(1-84), and were linked to long-term CV risk.

Conclusions:

  • Elevated sFlt-1 levels are present in patients with heart failure.
  • sFlt-1 is associated with HF severity and various biomarkers of cardiovascular risk.
  • sFlt-1 may represent a potential biomarker for assessing cardiovascular risk in heart failure patients.

Keywords:
AldosteroneBNPGalectin-3ST2heart failureprognosis sFlt-1

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
544
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
717
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
660
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478